TTMI · TTM Technologies, Inc.

Current Thesis

TTM Technologies' AI circuit-board recovery thesis requires delivery of its Q3 revenue guidance and a weekly close above the former $131.61 shelf; a weekly close below $118.65 would end that recovery case. The 2026-09-11 adjusted close of $126.44 remains below the previously published $128 break condition, which had already failed by 2026-08-28. That earlier thesis remains invalidated.

The material development since the 2026-08-30 note is acquisition financing: on 2026-09-10, TTM priced $500 million of senior notes at 6.750%, due 2034. The release also identifies expected incremental term loans of $300 million and $800 million. These are announced financing components, not evidence that the acquisitions have closed. TTM pricing announcement.

The narrative is maturing — the order acceleration disclosed on 2026-08-05 is now followed by acquisition financing, while the 2026-09-11 close remains below July's broken shelf. This is an inference about the story's development, not a measured conclusion about investor flows. The recovery case has low conviction because the historical price failure is established and subsequent operating confirmation remains pending.

Bullish and bearish views on TTM Technologies, Inc.

The model's bull view on TTM Technologies, Inc. (TTMI), in brief: Orders exceeded quarterly shipments. TTM's 2026-08-05 Q2 call reported a book-to-bill ratio, which compares orders with shipments, of 1.49 overall and 1.63 commercially. The same call reported a $901 million backlog scheduled within 90 days; these are historical demand… The bear view: The broken structure remains unrepaired. Both cases follow in full.

Bull Case

• Orders exceeded quarterly shipments. TTM's 2026-08-05 Q2 call reported a book-to-bill ratio, which compares orders with shipments, of 1.49 overall and 1.63 commercially. The same call reported a $901 million backlog scheduled within 90 days; these are historical demand indicators, not completed Q3 revenue.
• Revenue guidance tests the expansion. The 2026-08-05 release forecast Q3 revenue of $1.100–1.140 billion after Q2 revenue of $1.004 billion. The recovery case requires revenue at least meeting that guide's lower bound; a miss would contradict the expected conversion of orders into sales. Filed Q2 release.
• Financing has a dated milestone. The 2026-09-10 announcement expects the note offering to close on 2026-09-24. Completion would establish that financing component; failure to close would invalidate that narrower execution milestone. TTM pricing announcement.

Bear Case

• The broken structure remains unrepaired. The adjusted market close on 2026-09-11 was $126.44, below both the former $128 condition and the 2026-07-24 close of $131.61. The supplied daily-bar series shows the shares down 34.8% over three months and 42.9% below their 52-week high.
• Acquisition earnings arrive later. TTM's 2026-08-17 Epiq announcement specified approximately $1.1 billion of cash consideration and expected accretion to adjusted earnings per share during 2028. That management forecast does not establish near-term earnings support. Epiq acquisition announcement.
• Debt can precede acquisition completion. The 2026-09-10 release says the notes can close independently of Epiq. It specifies a 2026-11-15 acquisition outside date, automatically extendable to 2027-05-15 in certain circumstances, with redemption required if the stated conditions arise. TTM pricing announcement.

Setup & Price Structure

The measured change is a 2026-09-11 close of $126.44 versus $118.65 on 2026-08-28. The 14-period relative strength index (RSI) was 64.1 on 2026-09-11. Those observations establish a rebound; the supplied observations are too few to establish a durable base or expanding participation.

The $131.61 market close dated 2026-07-24 remains the recovery threshold. A weekly close above it, together with Q3 revenue meeting the $1.100 billion guidance floor, would satisfy the recovery case before invalidation. The $118.65 close dated 2026-08-28 supplies the new recovery test's failure threshold; it is a historical reference close, not a demonstrated support zone.

The supplied coverage includes a retrospective performance headline dated 2026-09-09 and market-mover coverage dated 2026-09-04. That sample is too small to establish retail crowding. Trading volume, short interest and moving-average levels are missing, so no claim about crowded ownership or distance above a rising average is supported.

Catalyst Calendar (next 30 days)

• 2026-09-24 — Expected note settlement. TTM's 2026-09-10 release names this date, subject to closing conditions. Settlement would confirm financing execution, not Epiq completion. Pricing announcement.
• ~2026-09-30, est. European acquisition checkpoint. The 2026-08-17 announcement expected Swiss Technology Group and ILFA to close in late Q3. This date represents that expected window, not a scheduled announcement; a company-disclosed delay would contradict the timetable. Acquisition update.

As checked on 2026-09-13, TTM's investor calendar lists no upcoming events. The next Q3 earnings release remains the operating test, but its date is unconfirmed and is not presented as a scheduled catalyst. TTM investor calendar.

What Would Change Our Mind

Failure to retain the rebound above the 2026-08-28 reference close would break this recovery thesis: a weekly close below $118.65 is the observable condition. Separately, Q3 revenue below the $1.100 billion guidance floor or total book-to-bill below 1.0 would contradict the operating case established by the 2026-08-05 release and call. The already-breached $128 condition remains a recorded failure of the earlier thesis.

Correlation Notes

This is a single-name recovery assessment; no current group participation evidence establishes a supporting sector move. TTM's 2026-08-05 call guided Data Center & Networking to roughly 49% of Q3 sales, providing an operating connection to AI infrastructure spending. Its commercial book-to-bill ratio of 1.63 on that call measures company orders, not stock-price correlation.

The 2026-08-17 Epiq announcement adds a defense-electronics acquisition to that exposure. Neither announcement supplies matched market-return observations, so a correlation coefficient or a claim that defense exposure offsets AI weakness would be unsupported.